The global acinetobacter pneumonia therapeutics market was estimated to be USD 300.9 million in 2023 and is expected to reach at USD 614.7 million by 2034 with a CAGR of 6.71% during the forecast period 2024-2034. Rising prevalence of Acinetobacter pneumonia bacterial infections, highlighting the urgent requirement for effective treatments that can overcome the limitations of existing antibiotic choices, ongoing research & development endeavors, surge in medical technology advancements, growing emphasis on personalized medicine, increasing aging population, rising prevalence of chronic diseases, growing need for innovative approaches, surge in resistance to current antibiotics, rising technological innovations in antimicrobial therapies & diagnostic tools, and increasing approval of novel acinetobacter pneumonia therapeutics are some of the key factors boosting the market growth.
Increasing approval of novel acinetobacter pneumonia therapeutics is predicted to boost the market growth during the forecast period. Acinetobacter pneumonia, a condition resulting from an opportunistic infection triggered by the Acinetobacter bacterium, poses a significant concern within healthcare settings, as these bacteria are increasingly recognized as significant pathogens worldwide. Given the limited treatment choices currently accessible for Acinetobacter pneumonia, market stakeholders are directing their efforts toward creating innovative pharmaceutical solutions. For instance, in May 2023, Innoviva Specialty Therapeutics has received FDA approval for XACDURO (sulbactam for injection; durlobactam for injection) to treat hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter. This approval signifies the introduction of the first pathogen-targeted therapy for Acinetobacter.
By drug class, cephalosporins was the highest revenue-grossing segment in the global acinetobacter pneumonia therapeutics market in 2023 owing to the escalation of antimicrobial resistance in Acinetobacter baumannii, rising incidence of pneumonia, surge in research & development efforts, and increasing number of clinical trial procedures. Additionally, sulbactam is predcited to grow at the fastest CAGR during the forecast period owing to its authorization to treat hospital-acquired bacterial pneumonia (HABP) & ventilator-associated bacterial pneumonia (VABP) in adults, rising introduction of new drugs, growing demand for effective treatments targeting multidrug-resistant strains of the Acinetobacter baumannii-calcoaceticus complex, and increasing approvals by regulatory authorities. For instance, in April 2023, Innoviva, Inc., a diversified holding company with various healthcare assets, revealed that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) unanimously voted 12-0 in favor of approving sulbactam-durlobactam. Acinetobacter baumannii-calcoaceticus complex susceptible strains are the source of both ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia in adults. The decision to treat these patients was made after a favorable evaluation of the benefits and risks of using this medication.
By route of administration, parenteral was the highest revenue-grossing segment in the global acinetobacter pneumonia therapeutics market in 2023 owing to the seriousness & urgency of Acinetobacter infections, growing introduction of new drug treatments, underscore the significance of rapid and direct administration of antibiotics through the intravenous (IV) route. This method ensures quick absorption and effectiveness, making it the preferred approach for managing severe infections such as Acinetobacter pneumonia. The predominance of the IV route corresponds with the critical nature of treating Acinetobacter pneumonia, highlighting the necessity for swift and precise therapy to achieve the best patient results. For instance, in October 2022, Shionogi & Co., Ltd. revealed that upcoming presentations at IDWeek 2022 will feature fresh data on Fetroja (cefiderocol), showcasing new real-world evidence that highlights the drug's robust effectiveness against challenging Gram-negative bacterial infections. Additionally, oral is predicted to grow at the fastest CAGR during the forecast period owing to the ease of accessing treatment promptly, the abundant availability of oral antibiotics, and growing acceptance of oral therapies reflect a global trend towards favoring oral medication usage. The oral route significantly contributes to offering effective and accessible treatment choices for acinetobacter pneumonia. Oral medications provide a convenient means of managing acinetobacter pneumonia, ensuring timely administration and fostering adherence to treatment plans.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global acinetobacter pneumonia therapeutics market in 2023 owing to the rising demand for effecient treatments and surge in collaborations among market leaders. For instance, in January 2024, Sanofi announced its plan to acquire the American biotechnology firm Inhibrx for up to $2.2 billion. The primary focus of the acquisition is INBRX-101, an investigational treatment for Alpha-1 Antitrypsin Deficiency (AATD), a rare hereditary condition causing gradual lung tissue deterioration. Additionally, retail pharmacies is predicted to grow at the fastest CAGR during the forecast period owing to the widespread accessibility of medications and the growing incidence of Acinetobacter pneumonia bacterial infection.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of recently introduced therapies, rising FDA authorizations, a robust healthcare infrastructure, elevated rates of Acinetobacter-related pneumonia instances, the uptick in multidrug-resistant strains, escalating demand for enhanced treatments, and increasing research & development activities. For instance, in January 2024, A study published in the Nature Journal unveiled a new clinical candidate that has shown efficacy against drug-resistant strains of Carbapenem-resistant Acinetobacter baumannii (Crab) in mouse models of pneumonia and sepsis. The experimental antibiotic, Zosurabalpin, is presently undergoing human trials and holds promise as a valuable treatment option for combating drug-resistant microbes. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in pneumonia cases, expansion of the medical tourism sector, rise in infection prevalence, growing healthcare spending, ongoing research & development endeavors concentrating on novel antibiotics & therapeutic approaches, and surge in regulatory approvals. For instance, in February 2023, Zai Lab Limited disclosed that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for sulbactam-durlobactam (SUL-DUR). This investigational drug, which combines sulbactam, a β-lactam antibiotic, and durlobactam, a novel broad-spectrum β-lactamase inhibitor, is intended for treating infections caused by Acinetobacter baumannii, including strains resistant to multiple drugs and carbapenems (CRAB).
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Increasing approval of novel acinetobacter pneumonia therapeutics is predicted to boost the market growth during the forecast period. Acinetobacter pneumonia, a condition resulting from an opportunistic infection triggered by the Acinetobacter bacterium, poses a significant concern within healthcare settings, as these bacteria are increasingly recognized as significant pathogens worldwide. Given the limited treatment choices currently accessible for Acinetobacter pneumonia, market stakeholders are directing their efforts toward creating innovative pharmaceutical solutions. For instance, in May 2023, Innoviva Specialty Therapeutics has received FDA approval for XACDURO (sulbactam for injection; durlobactam for injection) to treat hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter. This approval signifies the introduction of the first pathogen-targeted therapy for Acinetobacter.
By drug class, cephalosporins was the highest revenue-grossing segment in the global acinetobacter pneumonia therapeutics market in 2023 owing to the escalation of antimicrobial resistance in Acinetobacter baumannii, rising incidence of pneumonia, surge in research & development efforts, and increasing number of clinical trial procedures. Additionally, sulbactam is predcited to grow at the fastest CAGR during the forecast period owing to its authorization to treat hospital-acquired bacterial pneumonia (HABP) & ventilator-associated bacterial pneumonia (VABP) in adults, rising introduction of new drugs, growing demand for effective treatments targeting multidrug-resistant strains of the Acinetobacter baumannii-calcoaceticus complex, and increasing approvals by regulatory authorities. For instance, in April 2023, Innoviva, Inc., a diversified holding company with various healthcare assets, revealed that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) unanimously voted 12-0 in favor of approving sulbactam-durlobactam. Acinetobacter baumannii-calcoaceticus complex susceptible strains are the source of both ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia in adults. The decision to treat these patients was made after a favorable evaluation of the benefits and risks of using this medication.
By route of administration, parenteral was the highest revenue-grossing segment in the global acinetobacter pneumonia therapeutics market in 2023 owing to the seriousness & urgency of Acinetobacter infections, growing introduction of new drug treatments, underscore the significance of rapid and direct administration of antibiotics through the intravenous (IV) route. This method ensures quick absorption and effectiveness, making it the preferred approach for managing severe infections such as Acinetobacter pneumonia. The predominance of the IV route corresponds with the critical nature of treating Acinetobacter pneumonia, highlighting the necessity for swift and precise therapy to achieve the best patient results. For instance, in October 2022, Shionogi & Co., Ltd. revealed that upcoming presentations at IDWeek 2022 will feature fresh data on Fetroja (cefiderocol), showcasing new real-world evidence that highlights the drug's robust effectiveness against challenging Gram-negative bacterial infections. Additionally, oral is predicted to grow at the fastest CAGR during the forecast period owing to the ease of accessing treatment promptly, the abundant availability of oral antibiotics, and growing acceptance of oral therapies reflect a global trend towards favoring oral medication usage. The oral route significantly contributes to offering effective and accessible treatment choices for acinetobacter pneumonia. Oral medications provide a convenient means of managing acinetobacter pneumonia, ensuring timely administration and fostering adherence to treatment plans.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global acinetobacter pneumonia therapeutics market in 2023 owing to the rising demand for effecient treatments and surge in collaborations among market leaders. For instance, in January 2024, Sanofi announced its plan to acquire the American biotechnology firm Inhibrx for up to $2.2 billion. The primary focus of the acquisition is INBRX-101, an investigational treatment for Alpha-1 Antitrypsin Deficiency (AATD), a rare hereditary condition causing gradual lung tissue deterioration. Additionally, retail pharmacies is predicted to grow at the fastest CAGR during the forecast period owing to the widespread accessibility of medications and the growing incidence of Acinetobacter pneumonia bacterial infection.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of recently introduced therapies, rising FDA authorizations, a robust healthcare infrastructure, elevated rates of Acinetobacter-related pneumonia instances, the uptick in multidrug-resistant strains, escalating demand for enhanced treatments, and increasing research & development activities. For instance, in January 2024, A study published in the Nature Journal unveiled a new clinical candidate that has shown efficacy against drug-resistant strains of Carbapenem-resistant Acinetobacter baumannii (Crab) in mouse models of pneumonia and sepsis. The experimental antibiotic, Zosurabalpin, is presently undergoing human trials and holds promise as a valuable treatment option for combating drug-resistant microbes. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in pneumonia cases, expansion of the medical tourism sector, rise in infection prevalence, growing healthcare spending, ongoing research & development endeavors concentrating on novel antibiotics & therapeutic approaches, and surge in regulatory approvals. For instance, in February 2023, Zai Lab Limited disclosed that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for sulbactam-durlobactam (SUL-DUR). This investigational drug, which combines sulbactam, a β-lactam antibiotic, and durlobactam, a novel broad-spectrum β-lactamase inhibitor, is intended for treating infections caused by Acinetobacter baumannii, including strains resistant to multiple drugs and carbapenems (CRAB).
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Drug Class, Route Of Administration, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Acinetobacter Pneumonia Therapeutics Market Report 2023 - 2034
Acinetobacter Pneumonia Therapeutics Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Mn)
- β-Lactam Antibiotics
- Fluoroquinolone
- Aminoglycoside
- Carbapenem
- Glycylcycline
- Cephalosporins
- Polymyxins
- Sulfonamide
- Tetracycline
- Sulbactam
- Others
Acinetobacter Pneumonia Therapeutics Market Analysis & Forecast by Route Of Administration 2023 - 2034 (Revenue USD Mn)
- Oral
- Parenteral
- Others
Acinetobacter Pneumonia Therapeutics Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Mn)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Acinetobacter Pneumonia Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Acinetobacter Pneumonia Therapeutics Market: Drug Class Estimates & Trend Analysis
8. Acinetobacter Pneumonia Therapeutics Market: Route Of Administration Estimates & Trend Analysis
9. Acinetobacter Pneumonia Therapeutics Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Acinetobacter Pneumonia Therapeutics Market
12. Europe Global Acinetobacter Pneumonia Therapeutics Market
13. Asia Pacific Global Acinetobacter Pneumonia Therapeutics Market
14. Latin America Global Acinetobacter Pneumonia Therapeutics Market
15. MEA Global Acinetobacter Pneumonia Therapeutics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- GlaxoSmithKline Plc (GSK)
- AstraZeneca Plc
- Basilea Pharmaceutica
- Merck & Co. Inc.
- Johnson & Johnson
- Bayer AG
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
